Published in The Lancet, final overall survival results of the phase 3 TALAPRO-2 trial show that talazoparib plus enzalutamide significantly improves survival in patients with homologous recombination...
Read more
Minoryx Therapeutics today announce that the Marketing Authorization Application (MAA) for Minoryx’s lead candidate leriglitazone (NEZGLYAL®) has been submitted to the European Medicines Agency (EM...
Read more
Esta investigación del Cima forma parte de un proyecto financiado por el Gobierno de Navarra y abre la puerta ahora a un ensayo clínico con pacientes Los resultados conseguidos demuestran que e...
Read more
Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant...
Read more
Permite combinar en una sola herramienta el diagnóstico de alta precisión y la terapia dirigida con radiofármacos, como un misil inteligente que solo ataca el tumor
Read more
TRAINING-HR es el primer ensayo clínico que estudia específicamente el subgrupo de pacientes con ICFEp e incompetencia cronotrópica (dificultad del corazón para aumentar las pulsaciones durante el...
Read more
The results indicate that this system can detect prototypical abnormal gait patterns associated with peripheral neuropathies, such as ataxia—an uncoordinated or unstable gait—and steppage gait—a...
Read more
Researchers from the Research Institute of Hospital del Mar and the Barcelonaβeta Brain Research Center, the research center of the Pasqual Maragall Foundation, have demonstrated the benefits of foll...
Read more
It has been presented Upadacitinib as a new effective and safe therapeutic option for giant cell arteritis, an inflammatory disease that mainly affects the elderly and that until now had few treatment...
Read more
Oryzon Genomics, a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (...
Read more
According to the results, switching antidepressants or combining it with psychotherapy is more effective than increasing the dose in treatment-resistant patients with major depression.
Read more
The initiative, led by mjn-neuro with support from Biocat and several European partners, concludes three years of activity focused on driving innovative solutions to improve quality of life for people...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
